Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant durvalumab plus gemcitabine/platinum chemotherapy for operable upper tract urothelial carcinoma
2020-001028-32Phase 2Active
- Sponsor
- CHU Nîmes
- Start
- Sep 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, gemcitabine, cisplatin and carboplatin in upper tract urothelial carcinoma (UTUC) (2 cohorts), sponsored by CHU Nîmes. Primary endpoint: Pathological complete response rate. Started Sep 2020; status: active.
02
Drugs
durvalumabgemcitabinecisplatincarboplatin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2020-001028-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001028-32.